




The relative strengths and weaknesses of Regeneron Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regeneron Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Regeneron Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is 327%, being 107% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	1,206,012
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	163,550
Liabilities, Non-Current	7,259
Other Assets	494,538
Other Compr. Net Income	696
Other Expenses	-251,393
Other Liabilities	664,296
Other Net Income	-43,292
Other Revenues	1,378,477
Property and Equipment	379,940
Research and Development	625,554
Selling, General and Administrative Expense	210,755

Output Variable	Value in 1000 USD
Assets	2,080,490
Liabilities	835,105
Expenses	584,916
Revenues	1,378,477
Stockholders Equity	1,245,385
Net Income	750,269
Comprehensive Net Income	750,617
BaseVar	2,461,488
ECR before LimitedLiability	238%
Economic Capital Ratio	327%